B7-H1-, CD80-, and CD86-specific mRNA in unstimulated and in αCD3+αCD28-stimulated PBMCs of healthy controls and of HIV-infected patients
| . | Unstimulated PBMCs . | Anti-CD3+ αCD28-stimulated PBMCs . | ||||
|---|---|---|---|---|---|---|
| B7-H1 . | CD80 . | CD86 . | B7-H1 . | CD80 . | CD86 . | |
| Healthy controls (N = 22) | 24.3 ± 6.8* | 29.2 ± 8.3 | 44.7 ± 14.1 | 74.1 ± 14.2* | 57.1 ± 3.6 | 83.5 ± 22.4 |
| HIV-patients (N = 36) | 91.7 ± 17.3 | 38.9 ± 7.4 | 25.2 ± 5.8 | 151.8 ± 18.6 | 72.1 ± 8.9 | 43.6 ± 9.7 |
| . | Unstimulated PBMCs . | Anti-CD3+ αCD28-stimulated PBMCs . | ||||
|---|---|---|---|---|---|---|
| B7-H1 . | CD80 . | CD86 . | B7-H1 . | CD80 . | CD86 . | |
| Healthy controls (N = 22) | 24.3 ± 6.8* | 29.2 ± 8.3 | 44.7 ± 14.1 | 74.1 ± 14.2* | 57.1 ± 3.6 | 83.5 ± 22.4 |
| HIV-patients (N = 36) | 91.7 ± 17.3 | 38.9 ± 7.4 | 25.2 ± 5.8 | 151.8 ± 18.6 | 72.1 ± 8.9 | 43.6 ± 9.7 |
Protein/GAPDH ratio is presented. Mean values and SE are shown.
P < .05.